Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations

Life Sciences, Immunology, Neurology +11

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations · Full text

Life Sciences, Immunology, Neurology +11

The prevalence of MS in the United States

Mitchell T. Wallin, William J. Culpepper, Jonathan D. Campbell et al. · Neurology · 2019 · 1.1K citations · Full text

Public Health, Internal Medicine, Clinical Epidemiology +9

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

The CAMMS Trial Investigators · New England Journal of Medicine · 2008 · 1K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

Joanne Jones, Chia‐Ling Phuah, Amanda Cox et al. · Journal of Clinical Investigation · 2009 · 298 citations · Full text

Life Sciences, Immunology, Autoimmunity +13